CURIS INC (CRIS) Fundamental Analysis & Valuation

NASDAQ:CRIS • US2312693094

1.01 USD
-0.02 (-1.94%)
Last: Mar 10, 2026, 08:15 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CRIS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CRIS. CRIS was compared to 519 industry peers in the Biotechnology industry. Both the profitability and financial health of CRIS have multiple concerns. CRIS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. CRIS Profitability Analysis

1.1 Basic Checks

  • In the past year CRIS has reported negative net income.
  • CRIS had a negative operating cash flow in the past year.
  • CRIS had negative earnings in each of the past 5 years.
  • CRIS had a negative operating cash flow in each of the past 5 years.
CRIS Yearly Net Income VS EBIT VS OCF VS FCFCRIS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • CRIS has a worse Return On Assets (-132.25%) than 81.31% of its industry peers.
Industry RankSector Rank
ROA -132.25%
ROE N/A
ROIC N/A
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRIS Yearly ROA, ROE, ROICCRIS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • With an excellent Gross Margin value of 99.47%, CRIS belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CRIS has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for CRIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
CRIS Yearly Profit, Operating, Gross MarginsCRIS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. CRIS Health Analysis

2.1 Basic Checks

  • CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CRIS has more shares outstanding
  • The number of shares outstanding for CRIS has been increased compared to 5 years ago.
  • CRIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRIS Yearly Shares OutstandingCRIS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
CRIS Yearly Total Debt VS Total AssetsCRIS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • CRIS has an Altman-Z score of -67.90. This is a bad value and indicates that CRIS is not financially healthy and even has some risk of bankruptcy.
  • CRIS has a Altman-Z score of -67.90. This is amonst the worse of the industry: CRIS underperforms 92.29% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -67.9
ROIC/WACCN/A
WACC8.76%
CRIS Yearly LT Debt VS Equity VS FCFCRIS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • CRIS has a Current Ratio of 0.70. This is a bad value and indicates that CRIS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of CRIS (0.70) is worse than 89.02% of its industry peers.
  • CRIS has a Quick Ratio of 0.70. This is a bad value and indicates that CRIS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.70, CRIS is doing worse than 88.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.7
Quick Ratio 0.7
CRIS Yearly Current Assets VS Current LiabilitesCRIS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CRIS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 53.01% over the past year.
  • Looking at the last year, CRIS shows a quite strong growth in Revenue. The Revenue has grown by 13.56% in the last year.
  • The Revenue has been growing slightly by 1.75% on average over the past years.
EPS 1Y (TTM)53.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.18%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%8.36%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.21% on average over the next years. This is quite good.
  • Based on estimates for the next years, CRIS will show a very strong growth in Revenue. The Revenue will grow by 57.54% on average per year.
EPS Next Y63.06%
EPS Next 2Y31.9%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue Next Year17.66%
Revenue Next 2Y12.66%
Revenue Next 3Y28.44%
Revenue Next 5Y57.54%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRIS Yearly Revenue VS EstimatesCRIS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M
CRIS Yearly EPS VS EstimatesCRIS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

1

4. CRIS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRIS. In the last year negative earnings were reported.
  • Also next year CRIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRIS Price Earnings VS Forward Price EarningsCRIS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRIS Per share dataCRIS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

  • CRIS's earnings are expected to grow with 22.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.9%
EPS Next 3Y22.56%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRIS Dividend Analysis

5.1 Amount

  • CRIS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRIS Fundamentals: All Metrics, Ratios and Statistics

CURIS INC

NASDAQ:CRIS (3/10/2026, 8:15:57 PM)

1.01

-0.02 (-1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-30
Inst Owners31.55%
Inst Owner Change-1.12%
Ins Owners6.87%
Ins Owner Change0%
Market Cap13.87M
Revenue(TTM)11.65M
Net Income(TTM)-36.56M
Analysts81.82
Price Target14.28 (1313.86%)
Short Float %5.12%
Short Ratio1.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.99%
Min EPS beat(2)16.89%
Max EPS beat(2)25.09%
EPS beat(4)3
Avg EPS beat(4)12.17%
Min EPS beat(4)-3.2%
Max EPS beat(4)25.09%
EPS beat(8)5
Avg EPS beat(8)-0.2%
EPS beat(12)8
Avg EPS beat(12)0.44%
EPS beat(16)9
Avg EPS beat(16)-0.26%
Revenue beat(2)2
Avg Revenue beat(2)5.5%
Min Revenue beat(2)2.12%
Max Revenue beat(2)8.88%
Revenue beat(4)3
Avg Revenue beat(4)15.4%
Min Revenue beat(4)-10.12%
Max Revenue beat(4)60.74%
Revenue beat(8)5
Avg Revenue beat(8)10.15%
Revenue beat(12)6
Avg Revenue beat(12)4.79%
Revenue beat(16)7
Avg Revenue beat(16)1.63%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.81%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.19
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.67
EYN/A
EPS(NY)-1.83
Fwd EYN/A
FCF(TTM)-2.19
FCFYN/A
OCF(TTM)-2.19
OCFYN/A
SpS0.85
BVpS-1.07
TBVpS-1.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -132.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.47%
FCFM N/A
ROA(3y)-72.86%
ROA(5y)-52.24%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y0.85%
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.7
Quick Ratio 0.7
Altman-Z -67.9
F-Score4
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.18%
EPS Next Y63.06%
EPS Next 2Y31.9%
EPS Next 3Y22.56%
EPS Next 5Y14.21%
Revenue 1Y (TTM)13.56%
Revenue growth 3Y0.8%
Revenue growth 5Y1.75%
Sales Q2Q%8.36%
Revenue Next Year17.66%
Revenue Next 2Y12.66%
Revenue Next 3Y28.44%
Revenue Next 5Y57.54%
EBIT growth 1Y28.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.88%
EBIT Next 3Y-18.99%
EBIT Next 5Y1.48%
FCF growth 1Y25.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.74%
OCF growth 3YN/A
OCF growth 5YN/A

CURIS INC / CRIS FAQ

What is the fundamental rating for CRIS stock?

ChartMill assigns a fundamental rating of 2 / 10 to CRIS.


What is the valuation status of CURIS INC (CRIS) stock?

ChartMill assigns a valuation rating of 1 / 10 to CURIS INC (CRIS). This can be considered as Overvalued.


How profitable is CURIS INC (CRIS) stock?

CURIS INC (CRIS) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CRIS stock?

The Earnings per Share (EPS) of CURIS INC (CRIS) is expected to grow by 63.06% in the next year.